A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 986 in Healthy Subjects and Heart Failure Patients
Latest Information Update: 11 Aug 2022
At a glance
- Drugs Azelaprag (Primary) ; Azelaprag (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Sponsors Amgen
- 06 May 2019 Status changed from recruiting to discontinued.
- 19 Oct 2018 Planned End Date changed from 21 Dec 2018 to 30 Jul 2019.
- 19 Oct 2018 Planned primary completion date changed from 21 Dec 2018 to 30 Jul 2019.